Long-acting antipsychotic drugs for the treatment of schizophrenia: use in daily practice from naturalistic observations

Table 3 Weight and BMI changes reported in selected LAI publications

LAI(s) used	Reference	n	Weight change, mean difference, kg	BMI change, mean difference, kg/m²
Risperidone	[15]	715	1.4^***	0.5^***
Various	[48]	293	0.0^a	NR
Various	[52]	176	0.1	NR
Various	[53]	540	2.9^b	0.7^b
Various	[55]	1173	NR	0.2^b
Various	[58]	2399	−1.0^b	NR
Various	[61]	534	1.3^c	NR
Perphenazine	[78]	42	No weight change^d	NR
Risperidone	[79]	192	0.0	−0.1
Risperidone	[85]	1476	0.9	0.3
Risperidone	[86]	202	0.5	0.2
Various	[88]	565	0.9^*	NR
Risperidone	[90]	249	1.4^***	0.5^***
Risperidone	[105]	336	2.5	0.8
Risperidone	[108]	50	NR	0.0
Various	[112]	97	NR	1.5^b
Risperidone	[132]	67	−0.3	NR
Risperidone	[133]	529	1.0^***	0.6^***
Various	[134]	5950	NR	−0.7^e

Abbreviations: BMI = body mass index; LAI = long-acting injectable antipsychotic drugs; NR = not reported; pts = patients.
^aPts treated with in-range chlorpromazine-equivalent doses versus patients treated with higher chlorpromazine-equivalent doses.
^bVersus oral antipsychotics.
^cPts treated with LAI and anticholinergic drugs versus patients treated with LAI without anticholinergic drugs.
^dThis study reported no weight change, with 16 pts gaining a range of 1-9 kg and 7 pts losing a range of 1-2 kg.
^ePatients achieving persistent remission versus patients with prolonged disease.
^*p ≤ .05; ^** p ≤ .01; ^***p ≤ .001.

ISSN: 1471-244X